Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
Pipeline & Medicines
Product Pipeline & Portfolio
Theratechnologies develops and commercializes innovative therapies. The Company currently commercializes two products in the field of HIV. Trogarzo® and EGRIFTA SV® are approved in the United States. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.